The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Surgical endpoints are needed in lung cancer trials of neoadjuvant therapy
Jonathan Spicer, MD, PhD, McGill University, Montreal, Canada, highlights the importance of introducing new endpoints in clinical trials of neoadjuvant approaches for lung cancer. Assessment of the impact of neoadjuvant therapy on surgical outcomes is an important factor to consider in this growing field. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
